Eli Lilly drug wins FDA approval to lower cardiovascular risks

Eli Lilly diabetes drug wins FDA approval to lower cardiovascular risks - Heart disease is is the leading cause of death for ...

There’s a Vaccine That Could Lower Your Risk of Heart Attack—and Most People Aren’t Getting It

This shot could help to give you a health edge in more ways than one.
STAT

AstraZeneca and Ionis detail surprise failure of heart disease drug, with Alnylam closely watching

Roivant's autoimmune drug approval, Cytokinetics reports full data for heart condition treatment, and more biotech news ...

Mounjaro Is Now Approved to Lower the Risk of Heart Events

On Aug. 28, the U.S. Food and Drug Administration (FDA) approved Mounjaro to lower the risk of heart events, including heart ...
STAT

In autopsy of failed heart disease study, AstraZeneca raises broader questions about silencer drugs

AstraZeneca detailed the surprise failure of a closely watched heart disease trial, a study with ripple effects for a ...
Everyday Health on MSN

GLP-1 diabetes drug Mounjaro gets FDA okay to reduce heart attack and stroke

Research shows this tirzepatide GLP-1/GIP medication may help prevent cardiovascular emergencies in high-risk type 2 diabetes ...

Having a parent who lives past 100 is linked to a lower risk of heart disease and early death

Researchers say studying their children could help investigate the genetic and environmental factors that contribute to a ...

With the snip of a gene, scientists hope to erase high cholesterol for life

Gene editing reduced cholesterol by about 50% in an extremely small sample of patients over a year of follow-up, according to ...
Welltica+ on MSN

Heart doctor warns these symptoms should never be ignored

Discover the subtle, often overlooked symptoms of heart disease that a leading heart doctor warns should never be ignored.

First Horizon Executive Amy Perry Named Woman of Impact by the Mid-South Chapter of the American Heart Association

First Horizon Corporation (NYSE: FHN) is pleased to announce that Amy Perry, Executive Vice President and Operations ...

--Cytokinetics Phase 3 Trial Shows Aficamten Improves Heart Disease Symptoms

Cytokinetics (CYTK) said Friday its drug aficamten met both primary endpoints of a Phase 3 clinical trial treating a non-obstructive heart muscle disorder. The medication improved patient-reported ...